Chiral and non chiral determination of Dopa by capillary electrophoresis.
The suitability of capillary electrophoresis for determining the enantiomeric purity of levodopa in a pharmaceutical formulation also containing benserazide was assessed. To this end, the pharmaceutical components were separated in a non-chiral medium that allowed the total amount of Dopa and that of benserazide to be quantified. The addition of a chiral crown ether to the background electrolyte allows to separate the enantiomers of this compounds. Optimizing the variables influencing the enantioresolution of Dopa affords a resolution high enough resolution to determine the amount of dextrodopa (the distomer) contained in levodopa (the eutomer) in a pharmaceutical. A relative limit of detection (RLD) is proposed as a measure of the lowest detectable enantiomeric impurity. The RLD for the determination of dextrodopa contained in levodopa was 0.1% and found to depend on the enantiomer migration order. The enantiomeric purity of levodopa in the pharmaceutical preparation and dextrodopa from Sigma was 99.5 and 99.95%, respectively.
Blanco
Marcelo
M
Departamento de Química Analítica, Universidad Autónoma de Barcelona, E-08193 Bellaterra, Barcelona, Spain. marcel.blanco@uab.es
Valverde
Ismael
I
D001545:Benserazide / Q000032:analysis; D002138:Calibration; D004295:Dihydroxyphenylalanine / Q000032:analysis*; D015259:Dopamine Agents / Q000032:analysis*; D004338:Drug Combinations; D019075:Electrophoresis, Capillary; D005079:Excipients; D006863:Hydrogen-Ion Concentration; D007202:Indicators and Reagents; D015203:Reproducibility of Results; D013237:Stereoisomerism; D013607:Tablets
D015259:Dopamine Agents; D004338:Drug Combinations; D005079:Excipients; D007202:Indicators and Reagents; D013607:Tablets; D004295:Dihydroxyphenylalanine; D001545:Benserazide